There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gamida Cell Ltd (GMDA) and Regeneron (REGN) with bullish sentiments.
Gamida Cell Ltd (GMDA)
In a report released yesterday, Mark Breidenbach from Oppenheimer reiterated a Buy rating on Gamida Cell Ltd, with a price target of $20. The company’s shares closed yesterday at $7.30, close to its 52-week low of $6.65.
Breidenbach said:
“Tuesday, Gamida Cell reported 1Q earnings and reviewed recent progress. On the conference call, management reiterated prior guidance that enrollment in the Phase 3 trial of omidubicel (formerly known as NiCord) in hematopoietic stem cell (HSC) transplants remains on track to complete by year-end, with topline data expected in 1H20. In 2H19, updated results from an academic-sponsored trial of GDA-201 (formerly NAM-NK) in hematologic malignancies could reinforce previously reported encouraging data for the adoptive NK cell product, and the company is planning to initiate a multi-center Phase 1/2 trial of cryopreserved GDA-201 in 2020 focusing on non-Hodgkin’s lymphoma (NHL). With Gamida having sufficient cash to support operations through Phase 3 data of omidubicel, we reiterate our Outperform rating, $20 PT.”
According to TipRanks.com, Breidenbach is a 2-star analyst with an average return of 0.5% and a 42.6% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Alpine Immune Sciences Inc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gamida Cell Ltd with a $20 average price target.
See today’s analyst top recommended stocks >>
Regeneron (REGN)
In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Regeneron, with a price target of $480. The company’s shares closed yesterday at $322.40.
Singh commented:
“Regeneron (REGN) reported 1Q19 sales/earnings and provided an investor update. Despite the expectations for a seasonally weak 1Q19, OpEx control loosened uncharacteristically from the previous year. That being said, the robust fundamental business, which we expect could significantly reduce concentration in wet AMD from post-non-proliferative diabetic retinopathy (NPDR) approval and see strong growth from the ongoing Dupixent launch, remains intact. Management hosted a call which highlighted the company’s best-in-peer-group pipeline, though we believe investors may scrutinize at what cost. Considering the steep sell-off in 2Q (-21.48%, versus NBI Index -5.56% and XBI -6.37%), we view the current level as a compelling risk/reward opportunity for investors. We update our model for the quarter and stay bullish.”
According to TipRanks.com, Singh is a 2-star analyst with an average return of 0.6% and a 41.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Strongbridge Biopharma Plc, and Catabasis Pharmaceuticals.
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $420.80, representing a 30.5% upside. In a report released yesterday, Leerink Partners also reiterated a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
